Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More

Spotlight

Editas News

September 22, 2014
FierceBiotech names Editas Medicine as one of its Fierce 15 Biotech Companies of 2014 Read More

June 24, 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer Read More

May 14, 2014
2014 NEVY Awards: Editas Medicine Wins Hottest Healthcare Startup Read More

April 25, 2014
Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers Read More

April 15, 2014
Editas Medicine Co-Founder is awarded First Patent for Engineered CRISPR-Cas9 System   Read More

February 13, 2014
Editas Medicine Co-Founder Publishes Key CRISPR Complex Structure in Cell Read More

February 7, 2014
Editas Medicine Co-founder Publishes High-Resolution Structures of Major Cas9 Enzymes in Science Read More

Publications

June 6, 2014
Cell: Development and Applications of CRISPR-Cas9 for Genome Engineering. Read More

April 25, 2014
Nature Biotechnology: Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Read More

April 25, 2014
Nature Biotechnology: Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Read More

February 13, 2014
Cell: Crystal structure of Cas9 in complex with guide RNA and target DNA. Read More

February 6, 2014
Science: Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Read More

January 29, 2014
Nature: DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Read More

January 26, 2014
Nature Biotechnology: Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Read More